TechNavio recognizes the following companies as the key players in the Global Diabetic Retinopathy Drugs Market: Roche Holding Ltd., Novartis International AG, Pfizer Inc., and Eli Lilly and Co.
Commenting on the report, an analyst from TechNavio’s Healthcare team said: ”A current trend witnessed in the Global Diabetic Retinopathy Drugs market is the use of combination therapies for treating diabetic retinopathy. Until recently, laser treatment was the only available therapy but it does not cure the disease; it just slows or stops the advancement of it. Now two more treatments are available: vitrectomy and injection of corticosteroids or anti-VEGF. The entire treatment of diabetic retinopathy is usually very long, so single treatments are not effective enough to control the disease. Some of the most common combination therapies are vitrectomy followed or accompanied by laser treatment, ranibizumab along with macular laser photocoagulation, and bevacizumab with macular laser photocoagulation. Currently, laser treatment combined with multiple injections of anti-VEGF drugs is the most recommended treatment for diabetic retinopathy. This trend will have a positive impact on the growth of the market.”
According to the report, one of the major drivers is the worldwide increase in the number of diabetic patients because of hereditary issues and sedentary lifestyles. This will increase the prevalence of diabetic retinopathy, which in turn will increase the demand for drugs that can treat the condition.
Further, the report states that one of the major challenges is the availability of effective surgical treatments such as laser surgery and vitrectomy for the treatment of non-proliferative and proliferative diabetic retinopathy.
The report also includes a discussion of the other vendors operating in this market. The other vendors in the market are Vitreoretinal Technologies Inc., Torrent Pharmaceuticals Ltd., ThromboGenics NV, Allergan Inc., Ampio Pharmaceuticals Inc., Eyetech Inc., Isis Pharmaceuticals Inc., iCo Therapeutics Inc., OPKO Health Inc., pSivida Corp., Quark Pharmaceuticals Inc., and Sirnaomics Inc.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. For further information on this report, please visit https://www.technavio.com/content/global-diabetic-retinopathy-market-2012…
TechNavio, the market research platform of Infiniti Research Ltd., publishes periodic market research reports on niche and emerging technologies. For more information on our Engineering market research, please visit https://www.technavio.com/healthcare
Follow us on Twitter @ Technavio
TechNavio Announces the Publication of its Research Report-Global Diabetic Retinopathy Drugs Market 2012-2016
